| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439617 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
Using a multiplex testing approach, 28% of CUP carried one or more predictive biomarkers (MSI-H, PD-L1 and/or TML-H) to the immune checkpoint blockade, providing a novel option for treatment in patients with CUP.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Zoran Gatalica, Joanne Xiu, Jeff Swensen, Semir Vranic,